Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Linsidomine + moxisylyte for ED

Oct. 3, 1997

Effects of BQ-123 and BQ-788 on ET-1-induced corpus cavernosum contractions

Oct. 3, 1997

Intracavernous moxisylyte recommended for first-line treatment of ED

Oct. 3, 1997

BioTime completes phase III trial with blood volume plasma extender

Oct. 3, 1997

First registration filing for Unigene's injectable calcitonin product

Oct. 2, 1997

Quinacrine sterilization reviewed

Oct. 2, 1997

New agents for NIDDM presented by Pharmacia & Upjohn

Oct. 1, 1997

Pfizer seeks U.S. and European approval for Viagra

Sep. 30, 1997

Amgen to emphasize calcimimetics program; preliminary phase II results reported for R-568

Sep. 30, 1997

LY-333334: new bone anabolic agent from Lilly

Sep. 30, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 6, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...